[Quality assured HER2 analysis in breast cancer. Important therapeutic predictive and prognostic factor].
Fernö
Mårten
M
Institutionen för kliniska vetenskaper, avdelningen för onkologi, Lunds universitet.
Haglund
Monica
M
Bendahl
Pär-Ola
PO
Olsson
Hans
H
Rydén
Lisa
L
D000911:Antibodies, Monoclonal / Q000627:therapeutic use; D061067:Antibodies, Monoclonal, Humanized; D000970:Antineoplastic Agents / Q000627:therapeutic use; D014408:Biomarkers, Tumor / Q000032:analysis*; D001943:Breast Neoplasms / Q000175:diagnosis* / Q000188:drug therapy / Q000378:metabolism / Q000473:pathology; D018450:Disease Progression; D005260:Female; D006801:Humans; D007150:Immunohistochemistry / Q000592:standards; D017404:In Situ Hybridization, Fluorescence / Q000592:standards; D011237:Predictive Value of Tests; D011379:Prognosis; D011785:Quality Assurance, Health Care; D018719:Erb-b2 Receptor Tyrosine Kinases / Q000032:analysis* / Q000378:metabolism; D015203:Reproducibility of Results; D018570:Risk Assessment; D011795:Surveys and Questionnaires; D000068878:Trastuzumab
D000911:Antibodies, Monoclonal; D061067:Antibodies, Monoclonal, Humanized; D000970:Antineoplastic Agents; D014408:Biomarkers, Tumor; D018719:Erb-b2 Receptor Tyrosine Kinases; D000068878:Trastuzumab